RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

C. J A Punt, M. J A De Jonge, S. Monfardini, G. Daugaard, W. Fiedler, B. Baron, D. Lacombe, P. Fumoleau

Research output: Contribution to journalArticle

Abstract

Camptothecins have shown efficacy in terms of response rate in patients with small cell lung cancer (SCLC). RFS2000 is a new camptothecin derivative, which has shown objective responses in various tumour types. The aim of this phase II study was to determine the objective response rate of RFS2000 in patients with sensitive and refractory SCLC. RFS2000 was given orally at 1.5 mg/m2 per day for five consecutive days (five days on - two days off) on a continuous basis. Patients were evaluated weekly for toxicity and every six weeks for response. Thirty seven patients were included, 36 patients (14 with sensitive and 22 with refractory SCLC) were evaluable for toxicity, and 35 patients were evaluable for response. No objective responses were observed. Toxicity was acceptable, with myelosuppression, nausea/vomiting, and diarrhoea as the main toxicities. RFS2000 therefore has an acceptable toxicity profile but is not active as a single agent in SCLC.

Original languageEnglish
Pages (from-to)1332-1334
Number of pages3
JournalEuropean Journal of Cancer
Volume40
Issue number9
DOIs
Publication statusPublished - Jun 2004

Fingerprint

Small Cell Lung Carcinoma
Pharmaceutical Preparations
Camptothecin
Nausea
Vomiting
rubitecan
Diarrhea
Neoplasms

Keywords

  • Chemotherapy
  • EORTC
  • Phase II study
  • RFS2000
  • Rubitecan
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Punt, C. J. A., De Jonge, M. J. A., Monfardini, S., Daugaard, G., Fiedler, W., Baron, B., ... Fumoleau, P. (2004). RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. European Journal of Cancer, 40(9), 1332-1334. https://doi.org/10.1016/j.ejca.2004.02.016

RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. / Punt, C. J A; De Jonge, M. J A; Monfardini, S.; Daugaard, G.; Fiedler, W.; Baron, B.; Lacombe, D.; Fumoleau, P.

In: European Journal of Cancer, Vol. 40, No. 9, 06.2004, p. 1332-1334.

Research output: Contribution to journalArticle

Punt, CJA, De Jonge, MJA, Monfardini, S, Daugaard, G, Fiedler, W, Baron, B, Lacombe, D & Fumoleau, P 2004, 'RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group', European Journal of Cancer, vol. 40, no. 9, pp. 1332-1334. https://doi.org/10.1016/j.ejca.2004.02.016
Punt, C. J A ; De Jonge, M. J A ; Monfardini, S. ; Daugaard, G. ; Fiedler, W. ; Baron, B. ; Lacombe, D. ; Fumoleau, P. / RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group. In: European Journal of Cancer. 2004 ; Vol. 40, No. 9. pp. 1332-1334.
@article{51bfd8d947b3423f876516a0945829b6,
title = "RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group",
abstract = "Camptothecins have shown efficacy in terms of response rate in patients with small cell lung cancer (SCLC). RFS2000 is a new camptothecin derivative, which has shown objective responses in various tumour types. The aim of this phase II study was to determine the objective response rate of RFS2000 in patients with sensitive and refractory SCLC. RFS2000 was given orally at 1.5 mg/m2 per day for five consecutive days (five days on - two days off) on a continuous basis. Patients were evaluated weekly for toxicity and every six weeks for response. Thirty seven patients were included, 36 patients (14 with sensitive and 22 with refractory SCLC) were evaluable for toxicity, and 35 patients were evaluable for response. No objective responses were observed. Toxicity was acceptable, with myelosuppression, nausea/vomiting, and diarrhoea as the main toxicities. RFS2000 therefore has an acceptable toxicity profile but is not active as a single agent in SCLC.",
keywords = "Chemotherapy, EORTC, Phase II study, RFS2000, Rubitecan, Small cell lung cancer",
author = "Punt, {C. J A} and {De Jonge}, {M. J A} and S. Monfardini and G. Daugaard and W. Fiedler and B. Baron and D. Lacombe and P. Fumoleau",
year = "2004",
month = "6",
doi = "10.1016/j.ejca.2004.02.016",
language = "English",
volume = "40",
pages = "1332--1334",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "9",

}

TY - JOUR

T1 - RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

AU - Punt, C. J A

AU - De Jonge, M. J A

AU - Monfardini, S.

AU - Daugaard, G.

AU - Fiedler, W.

AU - Baron, B.

AU - Lacombe, D.

AU - Fumoleau, P.

PY - 2004/6

Y1 - 2004/6

N2 - Camptothecins have shown efficacy in terms of response rate in patients with small cell lung cancer (SCLC). RFS2000 is a new camptothecin derivative, which has shown objective responses in various tumour types. The aim of this phase II study was to determine the objective response rate of RFS2000 in patients with sensitive and refractory SCLC. RFS2000 was given orally at 1.5 mg/m2 per day for five consecutive days (five days on - two days off) on a continuous basis. Patients were evaluated weekly for toxicity and every six weeks for response. Thirty seven patients were included, 36 patients (14 with sensitive and 22 with refractory SCLC) were evaluable for toxicity, and 35 patients were evaluable for response. No objective responses were observed. Toxicity was acceptable, with myelosuppression, nausea/vomiting, and diarrhoea as the main toxicities. RFS2000 therefore has an acceptable toxicity profile but is not active as a single agent in SCLC.

AB - Camptothecins have shown efficacy in terms of response rate in patients with small cell lung cancer (SCLC). RFS2000 is a new camptothecin derivative, which has shown objective responses in various tumour types. The aim of this phase II study was to determine the objective response rate of RFS2000 in patients with sensitive and refractory SCLC. RFS2000 was given orally at 1.5 mg/m2 per day for five consecutive days (five days on - two days off) on a continuous basis. Patients were evaluated weekly for toxicity and every six weeks for response. Thirty seven patients were included, 36 patients (14 with sensitive and 22 with refractory SCLC) were evaluable for toxicity, and 35 patients were evaluable for response. No objective responses were observed. Toxicity was acceptable, with myelosuppression, nausea/vomiting, and diarrhoea as the main toxicities. RFS2000 therefore has an acceptable toxicity profile but is not active as a single agent in SCLC.

KW - Chemotherapy

KW - EORTC

KW - Phase II study

KW - RFS2000

KW - Rubitecan

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=2942574452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942574452&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2004.02.016

DO - 10.1016/j.ejca.2004.02.016

M3 - Article

C2 - 15177492

AN - SCOPUS:2942574452

VL - 40

SP - 1332

EP - 1334

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 9

ER -